BEAM
Beam Therapeutics Inc.
Is BEAM Halal?
Base editing technology — gene therapy ethics apply.
What You Should Know
Precision gene editing for genetic diseases. Its March 31, 2026 Form 10-Q reports $1,480.798 million of assets, $250.822 million of conservative debt and leases, $288.291 million of cash, $923.361 million of marketable securities and $31.738 million of quarterly revenue. Debt/assets is 16.94% and receivables-plus-cash/assets is 19.47%, but liquidity/assets is 81.83% and disclosed interest and other income is 31.08% of revenue. The examined financial screens fail; consult an Islamic bioethics scholar.
⚠️ Concerns
- •Ethical considerations
- •Early stage
- •Liquidity and income screens fail
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
250.822 / 1,480.798
1,211.652 / 1,480.798
288.291 / 1,480.798
9.867 / 31.738
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 81.83%, above the examined 33.333% limit, and disclosed interest and other income is 31.08% of revenue; debt/assets is 16.94% and receivables-plus-cash/assets is 19.47%.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 81.83%, above the examined 33.33% limit; debt/assets and receivables-plus-cash remain below the examined limits.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 81.83%, above the examined Malaysia 33% limit; debt/assets is 16.94%. This calculation is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Beam develops precision gene-editing therapies. Therapeutic healthcare is generally permissible, while gene-editing boundaries, licensing and product allocation require qualified scholarly review.
Limitation: The filing does not provide a universal prohibited-activity numerator across collaborations and therapeutic programs.
Purification
Beam discloses $9.867 million of interest and other income, but no scholar-approved purification percentage is asserted for the operating business.
Inputs, assumptions and primary sources
- Amounts are USD millions from Beam Therapeutics' March 31, 2026 Form 10-Q.
- Conservative debt includes $100.193 million long-term debt and $150.629 million of current and noncurrent operating-lease liabilities.
- Cash and cash equivalents are $288.291 million and current marketable securities are $923.361 million; no separate accounts-receivable balance is tagged in the filing facts.
- Quarterly revenue is $31.738 million and disclosed interest and other income is $9.867 million, or 31.08% of revenue.
- Base-editing therapeutics are generally permissible in the retained qualitative analysis, but bioethics and clinical-program allocation remain case-dependent.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →